Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,445 stopped studies mapped to Lymphoid Neoplasm and descendants · 89% state a reason
Over the 1,445 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01114256 | FNA Tumor Sampling for CD137 Modulation: A Pilot Study | — | terminated | May 3, 2010 | Stanford University | not stated | Not stated |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the… | Phase 2 / Phase 3 | terminated | Jul 14, 2008 | University of Alabama at Birmingham | Accrual goals could not be met within a timely manner | Enrollment / accrual |
| NCT00837200 | Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies | Phase 2 | terminated | Feb 5, 2009 | Milton S. Hershey Medical Center | PI said to close accrual do to funding | Enrollment / accrual |
| NCT00843310 | Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple… | Phase 2 | terminated | Feb 13, 2009 | NYU Langone Health | Due to slow accrual | Enrollment / accrual |
| NCT02658396 | GO-203-2C + Bortezomib For Relapsed Or Refractory MM | Phase 1 | withdrawn | Jan 18, 2016 | Dana-Farber Cancer Institute | Study was never open due to lack of funding | Funding |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT02408042 | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | Phase 1 / Phase 2 | withdrawn | Apr 3, 2015 | Western Regional Medical Center | not stated | Not stated |
| NCT01251952 | Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation | Phase 1 | terminated | Dec 2, 2010 | Barbara Ann Karmanos Cancer Institute | Drug unavailable | Other (stated, no rule matched) |
| NCT01548573 | Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | Phase 2 | terminated | Mar 8, 2012 | University of Iowa | Met study stopping rules | Other (stated, no rule matched) |
| NCT01965834 | Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic… | Phase 2 | terminated | Oct 18, 2013 | University of Miami | Lack of adequate accrual. | Enrollment / accrual |
| NCT02619812 | Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning… | Phase 2 | terminated | Dec 2, 2015 | Mayo Clinic | Difficulty recruiting; pill burden and nausea were barriers | Enrollment / accrual |
| NCT01220297 | Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related… | Phase 2 | terminated | Oct 13, 2010 | Stanford University | Low accrual | Enrollment / accrual |
| NCT02951117 | A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants… | Phase 1 | withdrawn | Nov 1, 2016 | AbbVie | No participants enrolled | Enrollment / accrual |
| NCT00985140 | Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides | — | terminated | Sep 28, 2009 | Stanford University | Competing studies | Other (stated, no rule matched) |
| NCT00676806 | A Phase II Study of Umbilical Cord Blood Transplantation | Phase 2 | terminated | May 13, 2008 | Tufts Medical Center | Slow accrual | Enrollment / accrual |
| NCT01018927 | Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in… | — | terminated | Nov 25, 2009 | University of Arkansas | PI does not have time to continue study | Other (stated, no rule matched) |
| NCT01729338 | Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | Phase 2 | terminated | Nov 20, 2012 | Duke University | not stated | Not stated |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following… | Phase 2 | terminated | Oct 8, 2014 | St. Jude Children's Research Hospital | Investigator's decision. | Investigator |
| NCT00088881 | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients… | Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00934232 | Busulfan in Multiple Myeloma | Phase 1 | terminated | Jul 8, 2009 | Guido Tricot | PI left the institution | Investigator |
| NCT02595242 | Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma | Phase 1 | withdrawn | Nov 3, 2015 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | not stated | Not stated |
| NCT02623920 | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory…(S-BR) | Phase 2 | withdrawn | Dec 8, 2015 | University of Arizona | Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close study… | Enrollment / accrual |
| NCT00082017 | UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas | Phase 2 | terminated | Apr 28, 2004 | National Cancer Institute (NCI) | IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND. | Enrollment / accrual |
| NCT01625455 | Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary… | Phase 4 | terminated | Jun 21, 2012 | Vanderbilt University Medical Center | Difficulty recruiting. | Enrollment / accrual |
| NCT01282476 | Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 2 | terminated | Jan 25, 2011 | Massachusetts General Hospital | slow accrual | Enrollment / accrual |
| NCT01610999 | Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell… | Phase 1 | terminated | Jun 4, 2012 | Tufts Medical Center | Unavailability of study article | Other (stated, no rule matched) |
| NCT01889797 | Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden…(PrE0401) | Phase 2 | terminated | Jun 28, 2013 | PrECOG, LLC. | Closed due prolonged enrollment timelines | Enrollment / accrual |
| NCT00681044 | HD Melphalan and SCT in Patients With IGDD or LCDD | Phase 2 | terminated | May 20, 2008 | Boston Medical Center | Poor accrual | Enrollment / accrual |
| NCT02802163 | Induction Therapy for Multiple Myeloma With Carfilzomib,… | Phase 1 / Phase 2 | withdrawn | Jun 16, 2016 | H. Lee Moffitt Cancer Center and Research Institute | study drug unavailable | Other (stated, no rule matched) |
| NCT00109889 | S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma | Phase 2 | terminated | May 4, 2005 | SWOG Cancer Research Network | poor accrual | Enrollment / accrual |
| NCT00710151 | Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International… | — | terminated | Jul 4, 2008 | OHSU Knight Cancer Institute | not stated | Not stated |
| NCT01750762 | Lenalidomide After Allo Transplant | Phase 1 | terminated | Dec 17, 2012 | Beth Israel Deaconess Medical Center | not stated | Not stated |
| NCT00645359 | Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large…(dMRI) | — | terminated | Mar 27, 2008 | University of Michigan Rogel Cancer Center | Insufficient resources to evaluate pilot, second to shift in research priorities | Other (stated, no rule matched) |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | Phase 2 | terminated | Aug 2, 2010 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell… | Phase 2 | terminated | Jul 25, 2014 | Celldex Therapeutics | not stated | Not stated |
| NCT02227108 | Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia… | Phase 2 | terminated | Aug 27, 2014 | MedImmune LLC | The study was terminated prior to a planned interim analysis based on lack of required efficacy in… | Efficacy / futility |
| NCT00360776 | Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte… | Phase 2 | terminated | Aug 7, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01534143 | High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma… | Phase 2 | terminated | Feb 16, 2012 | Barbara Ann Karmanos Cancer Institute | Data was not collected, because funding was unavailable to continue study. | Funding |
| NCT02285244 | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | withdrawn | Nov 6, 2014 | James Blachly | Decision made by the Principal Investigator | Investigator |
| NCT02257684 | A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as… | Phase 2 | terminated | Oct 6, 2014 | Jazz Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem… | Phase 2 | terminated | Jun 17, 2008 | University of Arizona | Pentostatin/alemtuzumab regimen had greater risk of graft failure. | Other (stated, no rule matched) |
| NCT00490490 | Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy | Phase 2 | terminated | Jun 22, 2007 | Stanford University | Low Accrual | Enrollment / accrual |
| NCT01207765 | Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell… | Phase 2 | terminated | Sep 23, 2010 | Tufts Medical Center | changes in practice | Other (stated, no rule matched) |
| NCT01484314 | Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma | Phase 2 | terminated | Dec 2, 2011 | Dana-Farber Cancer Institute | Low accrual. | Enrollment / accrual |
| NCT00560352 | Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple… | Phase 1 | terminated | Nov 19, 2007 | Bristol-Myers Squibb | not stated | Not stated |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or…(VISMOLY) | Phase 2 | terminated | Sep 18, 2013 | The Lymphoma Academic Research Organisation | lack of efficacy | Efficacy / futility |
| NCT02473523 | Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma… | N/A | terminated | Jun 16, 2015 | St. Jude Children's Research Hospital | The principal investigator left the institution. | Investigator |
| NCT01878708 | A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell… | Early Phase 1 | terminated | Jun 17, 2013 | Dana-Farber Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT01954784 | Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With… | Phase 1 | terminated | Oct 7, 2013 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 3, 2017source: clinicaltrials